Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Autor:	Rodon J, Perez-Fidalgo A, Krop I, Burris H, Guerrero-Zotano A, Britten C, Becerra C, Schellens J, Richards D, Schuler M, Abu-Khalaf M, Johnson F, Ranson M, Edenfield J, Silva A, Hackl W, Quadt C, Demanse D, Duval V, Baselga J
Rok vydání:	2018
Zdroj:	CANCER CHEMOTHERAPY AND PHARMACOLOGY r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname
ISSN:	1432-0843
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::6302117b10c4545840a4581d2686ac99 https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1638 Zobrazit plný text záznamu Full text from SpringerLink